The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma

키워드

참고문헌 (49)

1. Landi F, "Calf circumference, frailty and physical performance among older adults living in the community", Clin Nutr, 33, pp.539~544 (2014)
2. Mijnarends DM, "Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people : a systematic review", J Am Med Dir Assoc, 14, pp.170~178 (2013)
3. Cruz-Jentoft AJ, "Sarcopenia : European consensus on definition and diagnosis : report of the European Working Group on sarcopenia in older people", Age Ageing, 39, pp.412~423 (2010)
4. Beaudart C, "Prevalence of sarcopenia : the impact of different diagnostic cut-off limits", J Musculoskelet Neuronal Interact, 14, pp.425~431 (2014)
5. Zillikens MC, "Whole-body and segmental bioelectrical-impedance analysis in patients with cirrhosis of the liver : changes after treatment of ascites", Am J Clin Nutr, 55, pp.621~625 (1992)
6. Hemmingsson E, "No apparent progress in bioelectrical impedance accuracy: validation against metabolic risk and DXA", Obesity(Silver Spring), 17, pp.183~187 (2009)
7. Dasarathy S, "Sarcopenia from mechanism to diagnosis and treatment in liver disease", J Hepatol, 65, pp.1232~1244 (2016)
8. Pedersen BK, "Exercise-induced myokines and their role in chronic diseases", Brain Behav Immun, 25, pp.811~816 (2011)
9. Pedersen BK, "Muscles and their myokines", J Exp Biol, 214(Pt 2), pp.337~346 (2011)
10. Pedersen BK, "Role of myokines in exercise and metabolism", J Appl Physiol, 103, pp.1093~1098 (2007)
11. Halmos T, "The secretory function of skeletal muscles and its role in energy metabolism and utilization", Orv Hetil, 155, pp.1469~1477 (2014)
12. Nishikawa H, "Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis", J Cachexia Sarcopenia Muscle, 8, pp.915~925 (2017)
13. Korean Liver Cancer Study Group, "2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Korean Journal of Radiology, 16(3), pp.465~522 (2015), 대한영상의학회[DOI]
14. Edge S, "AJCC cancer staging manual" (2010), Springer
15. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
16. Dodson RM, "Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies", J Gastrointest Surg, 17, pp.2123~2132 (2013)
17. Hamaguchi Y, "Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults", Nutrition, 32, pp.1200~1205 (2016)
18. Kalafateli M, "Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score", J Cachexia Sarcopenia Muscle, 8, pp.113~121 (2017)
19. Peng PD, "Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis", HPB(Oxford), 13, pp.439~446 (2011)
20. Lausen B, "Maximally selected rank statistics", Biometrics, 48, pp.73~85 (1992)
21. Lausen B, "Computational Statistics", pp.483~496 (1994), Physica-Verlag
22. Hosoyama T, "Role of serum myostatin during the lactation period", J Reprod Dev, 52, pp.469~478 (2006)
23. McNally EM, "Powerful genes--myostatin regulation of human muscle mass", N Engl J Med, 350, pp.2642~2644 (2004)
24. McPherron AC, "Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member", Nature, 387, pp.83~90 (1997)
25. Peng LN, "Healthy community-living older men differ from women in associations between myostatin levels and skeletal muscle mass", J Cachexia Sarcopenia Muscle, 9, pp.635~642 (2018)
26. Dasarathy S, "Sarcopenia associated with portosystemic shunting is reversed by follistatin", J Hepatol, 54, pp.915~921 (2011)
27. Loumaye A, "Role of activin A and myostatin in human cancer cachexia", J Clin Endocrinol Metab, 100, pp.2030~2038 (2015)
28. Breitbart A, "Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients", PLoS One, 8, pp.e80454~ (2013)
29. Jeanplong F, "Undernutrition regulates the expression of a novel splice variant of myostatin and insulin-like growth factor 1 in ovine skeletal muscle", Domest Anim Endocrinol, 52, pp.17~24 (2015)
30. Furihata T, "Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure", Int J Cardiol, 220, pp.483~487 (2016)
31. Zhou X, "Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival", Cell, 142, pp.531~543 (2010)
32. Wagner KR, "A phase I", IItrial of MYO-029 in adult subjects with muscular dystrophy, 2008, pp.63, 561~571
33. Hansen JS, "Circulating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio", J Clin Endocrinol Metab, 101, pp.550~560 (2016)
34. Zhang L, "The emerging role of follistatin under stresses and its implications in diseases", Gene, 639, pp.111~116 (2018)
35. McPherron AC, "Metabolic functions of myostatin and GDF11", Immunol Endocr Metab Agents Med Chem, 10, pp.217~231 (2010)
36. Kalinkovich A, "Sarcopenia--the search for emerging biomarkers", Ageing Res Rev, 22, pp.58~71 (2015)
37. Kreidl E, "Activins and follistatins : emerging roles in liver physiology and cancer", World J Hepatol, 1, pp.17~27 (2009)
38. Grusch M, "Deregulation of the activin", follistatin system in hepatocarcinogenesis, 2006, pp.45, 673~680
39. Rossmanith W, "Follistatin overexpression in rodent liver tumors : a possible mechanism to overcome activin growth control", Mol Carcinog, 35, pp.1~5 (2002)
40. Fabregat I, "TGF-β signalling and liver disease", FEBS J, 283, pp.2219~2232 (2016)
41. Nishida N, "Immune checkpoint blockade for the treatment of human hepatocellular carcinoma", Hepatol Res, 48, pp.622~634 (2018)
42. Tomoda T, "Prognotic impact of serum follistatin in patients with hepatocellular carcinoma", J Gastroenterol Hepatol, 28, pp.1391~1396 (2013)
43. Yang YM, "Inflammation and liver cancer : Molecular mechanisms and therapeutic targets", Semin Liver Dis, 39, pp.26~42 (2019)
44. Krabbe KS, "Inflammatory mediators in the elderly", Exp Gerontol, 39, pp.687~699 (2004)
45. Franceschi C, "Chronic inflammation(inflammaging)and its potential contribution to age-associated diseases", J Gerontol A Biol Sci Med Sci, 69(Suppl 1), pp.S4~S9 (2014)
46. Mikó A, "Gender difference in the effects of interleukin-6 on grip strength-a systematic review and meta-analysis", BMC Geriatr, 18, pp.107~ (2018)
47. Inácio Pinto N, "Cancer as a proinflammatory environment : metastasis and cachexia", Mediators Inflamm, 2015, pp.791060~ (2015)
48. Delogu W, "Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation", Dig Liver Dis, 51, pp.1400~1408 (2019)
49. Ebadi M, "Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis", J Cachexia Sarcopenia Muscle, 9, pp.1053~1062 (2018)

관련 논문AI추천